evaluate the pharmaceuticals company wegovy on glp-1 efficacy / effectiveness FDA has approved the first pill for weight loss, a milestone in the growth of the revolutionary drugs. The drug, a once-a-day tablet, is also approved for reducing cardiovascular Research shows GLP-1 drugs are

21.7% of patients achieved more than 20% weight loss compared to 0% placebo

The STEP 1 trial showed semaglutide 2.4 mg led to 14.9% weight loss over 68 weeks, while SURMOUNT-1 showed tirzepatide achieved up to 20.9% weight reductionapproaching bariatric surgery outcomes.[6] The SELECT trial (17,604 patients) found semaglutide reduced cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% and all-cause mortality by 19%, suggesting direct cardioprotective effects beyond weight loss.[4] In STEP-HFpEF, semaglutide produced 13.3% weight loss in heart failure patients and improved symptoms and physical function

More serious adverse effects include pancreatitis, gallbladder disease (cholelithiasis, cholecystitis), and acute kidney injury (particularly with severe dehydration from gastrointestinal symptoms)

Wellbutrins label also warns of high blood pressure and seizures and recommends prescribing with caution for anyone who has renal or hepatic impairment